SEC-sourced researchBeta

VKTX

Viking Therapeutics, Inc.

US markets

Data passport

CIK: 0001607678
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 28, 2026
SEC registry record: Operating company

Last updated: Oct 5, 2026, 8:05 PM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

VKTX · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	0.0000	Feb 11, 2026
December 2024	0.0000	Feb 11, 2026
December 2025	0.0000	Feb 11, 2026

Annual periods · USD

Period end	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	-359,639,000.0000	-278,685,000.0000	715,729,000.0000	76,667,000.0000	Feb 11, 2026
December 2024	-109,963,000.0000	-87,790,000.0000	908,321,000.0000	28,043,000.0000	Feb 11, 2026
December 2023	-85,895,000.0000	-73,376,000.0000	—	—	Feb 11, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$0	December 2025	Feb 11, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$0	December 2024	Feb 11, 2026	10-K
Net incomeNetIncomeLoss	-$359.64M	December 2025	Feb 11, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$278.69M	December 2025	Feb 11, 2026	10-K
Total assetsAssets	$715.73M	December 2025	Feb 11, 2026	10-K
Total liabilitiesLiabilities	$76.67M	December 2025	Feb 11, 2026	10-K

New filings

Explore methodology ↗